associated with cardiovascular and cerebrovascular disease. 1, 2 Much of the purported value of these drugs relates to their ability to inhibit thrombus formation on intravascular thrombogenic lesions. Such effects may be more readily quantitated in the laboratory environment than in a clinical setting. We selected a reliable in vivo thrombogenic lesion, 3 the endarterectomized canine carotid artery, to compare the purported antithrombotic properties of two of these agents in combination, aspirin and dipyridamole, to no treatment and heparin. It seemed reasonable to postulate that if these drugs could favorably alter the temporal profile of clot formation on a highly thrombogenic surface in the laboratory animal, then they might be expected to do so in thrombogenic atherosclerotic ulcers encountered in clinical practice. 
The Effect of Combined Aspirin and Dipyridamole Therapy on Thrombus Formation in an Arterial Thrombogenic Lesion in The Dog

Materials and Methods
Animal Preparations
We selected, from a homogenous population of 10 to 15 kg healthy male mongrel dogs, 30 animals for this study; after having completed the procedure in ten operated solely for standardizing the technique. One of us, H.G.D., with the aid of an operating microscope, performed bilateral 1 cm long common carotid artery endarterectomies in each animal and then closed the vessel primarily with a running 8-0 prolene suture. We have previously described preparation of this lesion in detail. 3 We assigned animals randomly to one of three groups on the basis of drugs administered: control, heparin, and aspirin-dipyridamole. In order to prevent a bias that might have developed from minor changes in surgical technique, the numbers of animals in each group were sequentially balanced throughout the duration of the study.
We gave no drugs with anticoagulant properties to the control group; 100 units/kg of heparin intravenously immediately prior to occlusion of the carotid arteries for endarterectomy, supplemented by 10 units/kg/hr starting four hours after surgery and continuing for four hours, (unless sacrificed earlier) to the heparin group; and 325 mg of aspirin and 50 mg of dipyridamole daily, beginning two weeks prior to surgery and continuing until death, in the aspirin-dipyridamole group. All dogs scheduled to survive longer than four hours after surgery received 600,000 units of long acting penicillin during the operation.
Vessel Evaluation
Preparations were terminated at intervals of 30 minutes; one, two, and four hours; one, two, and three days; one week; and one and three months after endarterectomy. There was one dog (two vessels) from each group studied at each of these time intervals. Prior to death, each vessel was re-exposed and retrograde common carotid angiography was performed via a catheter placed in the carotid artery distal to the surgical site. After angiography was completed, the common carotid artery was cannulated proximal to the site of endarterectomy with a No. 15 needle. With the catheter used for angiography still in place, the segment of artery containing the endarterectomy was thus isolated from the circulation. This isolated segment was gently flushed with normal saline to clear the vessel lumen of blood, then perfused with 250 cc glutaraldehyde (2% in 0.1 mol phosphate buffer, pH 7.4, at room temperature) over 30 minutes at a pressure of 100 mmHg.
A transverse section from the middle of the endarterectomy was taken for light microscopy and stained with hematoxylin and eosin. The remainder of the specimen was opened longitudinally, photographed, and prepared for scanning electron microscopy (SEM). The specimens for SEM were dehydrated with ethanol and dried with liquid carbon dioxide using the Sorvall critical point drying system. The specimens were mounted on aluminum stubs, coated with carbon and gold-palladium, and examined with an ETEC scanning electron microscope operating at 20 KV. Photographs were made on Polaroid type 55 film.
Results
Angiography
Angiographic findings are summarized in table 1. Vessels were classified as occluded, patent with clot (> 25% stenosis) or patent without clot. There were no occluded vessels in the antiplatelet group compared with six (30%) in the control group (p < 0.05) and one in the heparin group. Considering only the patent vessels, nineteen (95%) in the aspirin-dipyridamole group were completely free of thrombus at the endarterectomy site compared to 8 of 14 vessels (57%) in the control group and 13 of 19 vessels (68%) in the heparin group. Thus the antiplatelet group proved superior to both the control (p < 0.01) and the heparin group (p < 0.05) in terms of minimizing gross thrombus formation at the site of endarterectomy. There was no statistical difference between the antiplatelet and heparin groups in terms of patency but each group was significantly better than the control group (p < 0.05). The angiogram of a control animal sacrificed one hour after surgery, showing a large amount of soft clot compromising the vessel lumen at the surgical site, is compared to angiograms of one hour heparin and aspirin-dipyridamole arteries showing minimal narrowing at the suture line but no intravascular thrombus, in figure 1.
Histology
The findings on light microscopic review of vessel cross sections corroborated the angiographic estimate of patency in each case. The one hour control vessel showed a large amount of soft thrombus ( fig. 2a) , consistent with the angiographic appearance of this vessel ( fig. la) . The one hour heparin and aspirin-dipyridamole vessels ( fig. 2b and 2c) showed scant thrombus formation that was not appreciated on angiography.
Scanning Electron Microscopy
Endarterectomy resulted in removal of the intima, the internal elastic lamina, and varying amounts of the innermost media. The exposed denuded surface was primarily a rough irregular layer of elastic and collagen fibers. SEM studies highlighted the extreme thrombogenicity of this surface. Within 30 minutes of completion of endarterectomy in the control animal, the entire endarterectomized surface was covered with a fibrin-platelet layer of varying thickness. Thrombus formation resulted as red blood cells (RBCs) became enmeshed in the developing fibrin-platelet network. Some white blood cells were also found in the evolving thrombus.
When examined two hours after surgery, mural thrombus formation was quite prominent in the control vessel ( fig. 3a) , while being more moderate in the heparinized vessel ( fig. 3b) . The two hour antiplatelet vessel showed only a sparse fibrin-platelet complex with essentially no thrombus formation ( fig. 3c ). Thus at this acute post-operative stage the protective effect of aspirin-dipyridamole therapy was readily apparent. By two days after surgery, mural thrombus in the control vessel was less impressive than it had been in the more acute animals, i.e. 30 minutes to 24 hours. By comparison the antiplatelet vessel had a much cleaner surface at this stage, with a very thin and incomplete fibrin-platelet-RBC coating. There were no qualitative differences between the aspirin-dipyridamole and heparin vessels at the two-day stage. Mural thrombus resolution was well underway by one week and was essentially complete by one month after surgery. There were areas in control and heparin vessels in which mural thrombi organized and remained adherent to the vessel wall instead of lysing.
Discussion
A large body of knowledge has recently evolved regarding the role of the platelet in intravascular thrombosis. Aspirin, dipyridamole, and other drugs which inhibit platelet activity have been extensively studied in clinical situations, but results to date have not been conclusive regarding their clinical effectiveness. 1, 4 We found the combination of oral aspirin and dipyridamole to have a beneficial effect in limiting thrombus formation on a highly thrombogenic surface and, therefore, believe the present study lends strong support to the use of these agents clinically in thromboembolic disorders.
The pharmacology of these agents and the role of the platelet in thrombus formation have been the subject of several recent detailed reviews [6] [7] and will only be briefly outlined here. The initial event in thrombus formation involves adherence of a layer of platelets to subendothelial constituents, such as collagen, basement membrane, and microfibril, which are exposed by removal of the endothelium. [8] [9] [10] This is followed by release of platelet granules and the aggregation of am- bient platelets to form an enlarging platelet mass. ADP is released 11 and thromboxane A 2 is formed via the arachidonate pathway; 12 both of these substances promote further platelet aggregation. The coagulation cascade is activated, leading to the synthesis of thrombin, which is necessary for stabilization of the growing platelet mass. 13 It appears that aspirin exerts its primary antithrombotic effect by inhibiting thromboxane A 2 production via inhibition of platelet, 14 and possibly megakaryocyte, 16 cyclo-oxygenase. Thus aspirin will limit thromboxane A 2 -mediated platelet aggregation and release reactions. ADP-induced aggregation, adherence of platelets to collagen, release of platelet granule contents, and thrombin-induced aggregation and release do not require an intact arachidonate pathway; 6 therefore, aspirin should have little effect on thrombus formation mediated predominately by these mechanisms. The ideal antithrombotic dose of aspirin in humans has not been defined, but it has been suggested that a low dosage in the range of 160 to 325 mg/day is probably sufficient in many patients. 7 There have been reports that aspirin in higher doses may actually exert a thrombogenic effect via inhibition of vessel wall prostacyclin synthesis. 16,1? Although fairly high daily dosages of aspirin were used in the present study (20-30 mg/kg), the data do not suggest a thrombogenic effect of any anatomic significance.
Dipyridamole probably exerts its major antithrombotic effect by raising cyclic AMP levels via an inhibiting effect of platelet phosphodiesterase. 18, 19 Elevation of cyclic AMP levels leads to inhibition of a variety of platelet functions including: 1) platelet adherence to damaged vessel walls, 2) platelet aggregation, and 3) release of platelet granular contents. 5 Variable results have been reported in clinical and animal studies of this drug. 20, 21 In most studies in which dipyridamole has been found to be beneficial, it has been used in combination with another platelet-active drug or an anticoagulant. 20 Further studies comparing different platelet affecting agents, used in differing combinations and dosage schedules, would be of value. With increasing understanding of the pharmacology of these drugs, it would be possible to select combinations of agents that inhibit multiple different aspects of platelet function. Further work involving both animal studies and human clinical trials will be necessary to more exactly define the beneficial effects of these drugs in humans.
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